Alzheimer's Drug Discovery Foundation
VC Fund
New York, United States
Alzheimer's Drug Discovery Foundation is a VC fund in New York focused on Biotechnology and Health Care. The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity solely dedicated to finding effective drugs for Alzheimer’s disease. Our pioneering biomedical venture philanthropy approach allows us to invest in the most promising drug discovery and development programs around the world in both academic institutions andbiopharmaceutical companies. Since our founding in 1998, the ADDF has invested nearly $100 million to support over 500 programs across 18 countries.
- Total investments:
- 55
- Last investment:
- Lead investor:
- 73%
Last updated:
For AI agents: llms.txt
Industries Alzheimer's Drug Discovery Foundation invests in
Stages Alzheimer's Drug Discovery Foundation invests in
Countries Alzheimer's Drug Discovery Foundation invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Grant
- $250k–$5.8M
- Series A
- $2.1M–$85M
- Series B
- $6M–$73M
Investment Focus
Industry
- Biotechnology 32 (58%)
- Health Care 23 (42%)
- Medical 14 (25%)
- Health Diagnostics 13 (24%)
- Therapeutics 12 (22%)
Stage
- Grant 25 (45%)
- Series A 9 (16%)
- Series B 5 (9%)
- Venture - Series Unknown 4 (7%)
- Seed 3 (5%)
Country
- United States 29 (53%)
- Canada 3 (5%)
- Spain 2 (4%)
- United Kingdom 2 (4%)
- Sweden 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Howard Fillit
Co-Founder and Chief Science Officer
|
Co-Founder and Chief Science Officer | Total investments: 13 | Find email | |
Leonard Lauder
Co-Chairman & Co-Founder
|
Co-Chairman & Co-Founder | Total investments: 0 | Find email | |
Martin Tolar
Business Advisory Board & Scientific Review Board
|
Business Advisory Board & Scientific Review Board | Total investments: 0 | Find email | |
Meriel Owen
Director
|
Director | Total investments: 1 | Find email | |
|
Ronald S. Lauder
Co-Chairman and Co-Founder
|
Co-Chairman and Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AviadoBio
|
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK DementiaResearch Institute. | Grant / Mar 31, 2026 | |
MindImmune Therapeutics
|
MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated.Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs. | $5M / Grant / Mar 10, 2026 | |
Transposon Therapeutics
|
Transposon Therapeutics operates as a pharmaceutical company based in Westport, Connecticut. It specializes in developing therapeutics for debilitating and life-threatening diseases | $5M / Grant / Jul 09, 2025 | |
Circular Genomics
|
Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predictswhether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health. | $250K / Grant / Jul 08, 2025 | |
Life Molecular Imaging
|
Life Molecular Imaging is a heal diagnostic center that provides neuroimaging and cardiovascular imaging services. | $2.2M / Grant / May 14, 2025 | |
Alamar Biosciences
|
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California. | $10M / Grant / Jan 08, 2025 | |
University of Gothenburg
|
University of Gothenburg is a school in Gothenburg. | $1.2M / Grant / Nov 14, 2024 | |
GLX Analytix
|
GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark. | Venture - Series Unknown / Oct 29, 2024 | |
C2N Diagnostics
|
C2N Diagnostics is a specialty diagnostics company focused on providing laboratory services and products in brain health with innovative technologies. The C2N Diagnostics PrecivityAD Test helps physicians determine the presence of amyloid plaques in the brain, which is crucial for Alzheimer's diagnosis. C2N is known for its high-performanceblood biomarkers aimed at early diagnosis and therapeutic discovery related to brain health conditions. | $22M / Grant / Sep 25, 2024 | |
Neuro Therapia
|
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M / Series B / Aug 06, 2024 | |
| See all 55 investments → | |||
Co-Investors
Dolby Family Ventures
7 deals together
Cleveland Clinic
3 deals together
Brain Trust Accelerator Fund
2 deals together
Eli Lilly
2 deals together
Foundation for a Better World
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Alzheimer's Drug Discovery Foundation invest in?
Alzheimer's Drug Discovery Foundation invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Series A stage. Most of the 55 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alzheimer's Drug Discovery Foundation's check size?
Alzheimer's Drug Discovery Foundation typically joins rounds of $250k–$5.8M at Grant, $2.1M–$85M at Series A and $6M–$73M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alzheimer's Drug Discovery Foundation participates in.
How do I contact Alzheimer's Drug Discovery Foundation?
Public channels for Alzheimer's Drug Discovery Foundation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alzheimer's Drug Discovery Foundation?
The team at Alzheimer's Drug Discovery Foundation includes Howard Fillit (Co-Founder and Chief Science Officer), Leonard Lauder (Co-Chairman & Co-Founder) and Martin Tolar (Business Advisory Board & Scientific Review Board). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
